To date, T cells transduced with a genetic modified chimeric antigen receptor (CAR) to CD19 have had a clinically marked impact on patients with B-cell chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia, which are highly refractory and relapsed.3, 4, 5, 6, 7, 8 Patients injected with T cells harboring anti-CD19-CAR through the peripheral blood achieved complete and sustained remission, although T cells with anti-CD19-CAR unfortunately caused prolonged B-cell aplasia in these patients. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.